Results 31 to 40 of about 260,886 (316)

Targeting AXL in NSCLC

Lung Cancer: Targets and Therapy, 2021
State-of-the-art cancer precision medicine approaches involve targeted inactivation of chemically and immunologically addressable vulnerabilities that often yield impressive initial anti-tumor responses in patients. Nonetheless, these responses are overshadowed by therapy resistance that follows. AXL, a receptor tyrosine kinase with bona fide oncogenic
Zaman,Aubhishek, Bivona,Trever G
openaire   +4 more sources

Új lehetőségek az NSCLC szisztémás kezelésében

, 2023
Az irodalmi összefoglaló dolgozatom témája a nem kissejtes tüdőrák esetében vizsgálható prediktív biomarkerek, és ezáltal elérhető célzott terápiás kezelés.
Balog, Ádám
core  

Oxymatrine inhibits the development of radioresistance in NSCLC cells by reversing EMT through the DcR3/AKT/GSK-3β pathway

, 2023
Introduction Lung cancer is the leading cause of cancer-associated mortality globally. In particular, non-small cell lung cancer (NSCLC) constitutes the largest percentage of all cases of lung cancer.
Yu Cao, Jianming Tang, Hong Zhang, Rui Wang   +3 more
core   +1 more source

The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer

Исследования и практика в медицине, 2021
Currently, lung cancer is a global problem and public health issue in the world. Chemoradiotherapy remains the optimal method in the treatment of patients with unresectable non-small cell lung cancer (NSCLC).
E. I. Smolenov, G. V. Afonin, V. S. Usachev, D. D. Kudryavtsev, I. V. Kolobaev, S. A. Ivanov   +5 more
doaj   +1 more source

Pattern of care in locally advanced non-small cell lung cancer: A tertiary care experience from India

Lung India
Introduction and Objective: Heterogeneity in locally advanced (LA) Non-Small Cell Lung Cancer (NSCLC) group necessitates a multi-disciplinary approach to its management. Surgery is the standard of care treatment if resectable; otherwise, concurrent chemo-
Aswin Ravi, Sushmita Pathy, Supriya Mallick, Prabhat S. Malik, Sunil Kumar, Rajeev Kumar   +5 more
doaj   +1 more source

Long Noncoding RNA LINC01426 Sequesters microRNA-519d-5p to Promote Non-Small Cell Lung Cancer Progression by Increasing ETS1 Expression [Retraction]

Cancer Management and Research, 2023
Dai J, Wang B, Zhao Y, et al. Cancer Manag Res. 2020;12:12697–12708. At the authors request, the Editor and Publisher of Cancer Management and Research wish to retract the published article.
Dai J, Wang B, Zhao Y, Zuo X, Cui H, Chen X, Liu X   +6 more
doaj  

Role of Serum Tumor Markers in Prognosis of Operable Non-small Cell Lung Cancer Patients

Zhongliu Fangzhi Yanjiu, 2018
Objective To evaluate the prognostic value of CEA, CA125, CA199, NSE, CYFRA21-1 and SCC-Ag as serum tumor markers on the diagnosis of operable non-small cell lung cancer(NSCLC) after radical operation.
LI Shaolei, MA Yuanyuan, XIONG Ying, ZHANG Shanyuan, HUANG Miao, YANG Yue   +5 more
doaj   +1 more source

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC

Pharmaceutics, 2020
c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Unlike other c-Met inhibitors that fail clinically, ABN401 is a newly synthesized c-Met inhibitor that is not potentially ...
Nam Ah Kim, Sungyoul Hong, Ki Hyun Kim, Du Hyung Choi, Joo Seok Kim, Kyung Eui Park, Jun Young Choi, Young Kee Shin, Seong Hoon Jeong   +8 more
doaj   +1 more source

Pharmacoepidemiology analysis of high cost drugs used in the treatment of NSCLC in the upper Padua (Ulss 6 Euganea)

, 2023
reservedLo studio ha lo scopo di analizzare l’outcome delle terapie per il carcinoma del polmone non a piccole cellule nella real-life negli ospedali della Regione del Veneto di Camposampiero e Cittadella (Ulss Euganea n. 6).
LAZZARO, ROSSELLA
core  

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source